100 results about "Palate carcinoma" patented technology

This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and / or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.

The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.

The invention relates to an application of microRNA in preparation of a kit for diagnosis of cervical carcinoma or precancerous lesions. According to the invention, obvious low expression of miR-375 and miR-424 in tissues and cells of cervical carcinoma or precancerous lesions is revealed, and the low expression is obviously relative to the cervical carcinoma or precancerous lesions. The invention also provides a cervical carcinoma or precancerous lesions diagnosis method and the kit for determining existence amount of miR-375 and / or miR-424.

The invention discloses a Chinese medicinal formula for treating atrophic gastritis and precancerous lesion. The effective ingredients comprise the following Chinese medicinal herbs by weight: 10 to 50 grams of sauted pilose asiabell root, 10 to 50 grams of sauted large-headed atractylodes rhizome, 10 to 30 grams of tuckahoe, 5 to 20 grams of pinellia tuber, 5 to 20 grams of dried orange peel, 3 to 10 grams of raw licorice root, 5 to 15 grams of root powder of pseudo-ginseng, 5 to 20 grams of zedoary, 5 to 20 grams of Zhejiang fritillaria bulb, 15 to 60 grams of spreading hedyotis herb, 10 to 60 grams of hairy-vein agrimonia herb and bud, 10 to 60 grams of barbed skullcap herb, 5 to 20 grams of fruit of princesplume ladysthumb and 5 to 20 grams of creeping fig fruit. The Chinese medicinal formula has the effects of tonifying spleen, regulating qi, dissipating blood stasis and detoxifying, treats both principal and secondary aspects of diseases aiming at the pathogenesis of the chronic atrophic gastritis and precancerous lesion, has low recurrence rate after healing and good short-term and long-term curative effect, and has not toxic or side effect.

The invention relates to a kit for morbidity-related tumor suppressor gene epigenetic mutation detection of gastrointestinal neoplasms and application thereof. The kit mainly comprises 25 pairs of gastrointestinal neoplasm morbidity-related tumor suppressor gene promotor region CpG-island amplification and sequencing primers of 9 kinds and a polymerase chain reaction (PCR) amplification reagent. Through a PCR amplification product obtained through the kit, a gene CpG-island methylation state can be analyzed through the methods of methylation specific PCR (MSP), combined bisulphite-restrictionanalysis (COBRA) or bisulfite sequencing PCR (BSP) and the like. The kit has the efficient effect of detecting CpG-island methylation and is used for the morbidity-related tumor suppressor gene epigenetic mutation detection of the gastrointestinal neoplasms.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The invention discloses application of a cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, an expression vector and a diagnosis medicine, belonging to the field of medical biotechnology. Specifically, the invention provides application of the cancer suppressor gene FBXW7 in preparation of drugs used for preventing or treating breast tumors, the expression vector constructed from the gene FBXW7 and a vector pcDNA3.1 and a preparation method thereof, and the breast tumor diagnosis medicine at least including a pair of primers capable of specific amplification of the gene FBXW7 and composed of an upstream primer and a downstream primer. Expression of the cancer suppressor gene FBXW7 is closely related to breast cancer molecular subtyping; the cancer suppressor gene FBXW7 has specific low expression in a breast cancer with high grade malignancy and exerts an inhibitory effect on growth of breast cancer cells. Thus, screening of breast cancers with low expression of the gene has significant meaning to prognostic prediction of the breast cancers; and specific recovery of expression of the cancer suppressor gene in breast cancer cells provides a novel approach for targeted individualized treatment of the breast cancers.

The invention provides application of METRNL protein as a protein molecule marker for detecting colon cancer and application of the METRNL protein in preparing a colon cancer diagnostic reagent or a kit. Immunohistochemistry is carried out on 30 pairs of human colon cancer tissues and para-carcinoma tissues through immunohistochemistry tests, and the result proves that the METRNL protein has differential expression in cancer tissues and para-carcinoma tissues of the human colon cancer. Therefore, whether a patient has the colon cancer can be detected according to the expression quantity of the METRNL protein in colon tissues.

This invention relates to a pharmaceutical composition for inhibiting the growth and / or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor β (FRβ) protein of an FRβ (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FRβ (+) macrophage is distributed around pancreatic cancer cells at the invasive front.

The invention discloses a system used for predicting prognosis of a liver cancer patient. The system comprises a system for detecting expression quantities of four proteins c-Met, Caspase8, CXCR4 andP-P21, and a protein expression quantity data processing system. The system for detecting the expression quantities of the four proteins measures the expression quantities of the proteins through an immunohistochemistry staining method; and the protein expression quantity data processing system converts the expression quantities of the four proteins in a para-carcinoma tissue of the to-be-predicted liver cancer patient into prognosis score values, and predicts the prognosis of the liver cancer patient according to the prognosis score values.

The invention discloses an lncRNA molecule ENST00000438553 and application thereof in auxiliary diagnosis of nasopharyngeal carcinoma. The nucleotide sequence of ENST00000438553 is shown as SEQ ID NO.1. The expression quantity of TCONS_00003617 in nasopharyngeal carcinoma tissues is significantly higher than that of pericarcinomatous tissues. The lncRNA molecule ENST00000438553 can be used as a nasopharyngeal carcinoma molecular marker or target in early clinical diagnosis, prognosis or targeted therapy of nasopharyngeal carcinoma, and is beneficial to further explication of the occurrence and development mechanism, signal pathway and the like of nasopharyngeal carcinoma, thus having remarkable application prospect and theoretical value.

The invention relates to a method for establishing a pancreatic cancer model, and belongs to the technical field of the establishment of an animal model. According to the method, a slow virus for over-expressing one cancer gene and simultaneous knocking down two cancer suppressor genes is constructed according to cancer genes and cancer suppressor genes having the maximum mutation rate in human pancreatic cancer in TCGA database, and the slow virus is applied to the pancreas head of a tree shrew through orthotopic injection so as to induce pancreatic cancer of the tree shrew; and specifically, the method comprises the following steps: (1) construction of a slow virus vector; (2) virus packaging, titre determination and in vitro verification; (3) virus injection; and (4) monitoring and pathological investigation of the tree shrew. The method disclosed by the invention has the advantages that the method is short in inducing cycle, high and stable in morbidity, and simple and convenient in operation, and is capable of rapidly and effectively establishing a tree shrew pancreatic cancer model for simulating the genetic mechanism of human pancreatic cancer to the greatest extent; and the pancreatic cancer model is applicable to the research of the pathogenesis of human pancreatic cancer, the exploration of cancer therapy targets and the development of novel antineoplastic drugs, so as to offer a reference for the treatment of human pancreatic cancer.

The invention relates to a cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer and application. Active components of the medicinal composition include a chemotherapy medicine 10-hydroxycamptothecine and a targeting medicine crizotinib. The invention also relates to application of 10-hydroxycamptothecine and crizotinib in the field of cancer treatment drugs. According tothe cancer compound 10-hydroxycamptothecine and crizotinib for treating lung cancer, the anti-tumor medicine 10-hydroxycamptothecine and the targeting medicine crizotinib are used in match; the in vitro experiment verifies that the chemotherapy medicine 10-hydroxycamptothecine and the targeting medicine crizotinib are obviously synergistically interacted in killing malignant cells. The new application of the drug combination helps reducing the toxic and side effects of chemotherapy medicines; the drug resistance of the targeting medicine can also be reduced; the tumor inhibiting effect is improved; and scientific foundation is supplied to develop new drugs.

The invention discloses an lncRNA related to colorectal cancer and application thereof. An inventor conducts transcriptome lncRNA-mRNA sequencing analysis on cancer tissue and para-carcinoma tissue ofpatients suffering from the colorectal cancer, 1ncRNAs obvious in differential expression and co-expression genes thereof are sought, and LOC105374879 closely related to the colorectal cancer and co-expression genes of the LOC105374879 are found. Accordingly, a new molecular marker is provided for the early diagnosis of the colorectal cancer, and a foundation is laid for clinical application.

A method for determining if a subject with cancer or precancerous lesions or a benign tumor, will respond to treatment with an inhibitor selected from the group comprising an inhibitor of one or more enzymes in the mevalonate pathway, an inhibitor of geranylgeranyl transferase, an inhibitor of farnesyl transferase or an inhibitor of squalene synthase, by (i) obtaining a sample of the cancer cells, precancerous cells or benign tumor cells from the subject, (ii) assaying the cells in the sample for the presence of a mutated p53 gene or a mutant form of p53 protein or a biologically active fragment thereof, and (iii) if the cells have the mutated p53 gene or mutant form of the p53 protein, then determining that the subject will respond to treatment with the inhibitor or combinations thereof. Some embodiments are directed to treatment with the inhibitors.

The present invention provides a composition for the treatment of a tumour, comprising: (i) allogeneic or xenogeneic tumour cells; and (ii) a pharmaceutically acceptable excipient. If two or more heterozygous individuals have the same cancer / tumour of the same or similar histological grade, then transplantation of tumour / cancer tissue / cells from one individual to another will not only induce rejection of the transplanted tissue / cancer, but will also increase the immunological awareness of the immune system to peptides shared between the tumours / cancers and other tumours possessing similar peptides.

The invention discloses a biomarker for early breast cancer diagnosis. The biomarker is LINC01929. By the detection of tissue samples and paracancerous tissues of breast cancer in stage I-II, it is found that the expression level of LINC01929 in cancer tissues is significantly up-regulated, suggesting that LINC01929 can be used for the diagnosis and treatment of early breast cancer.

The invention discloses an application of dendrophenol in preparing medicines for inhibiting proliferation of cervical carcinoma cells and for inducing autophagic apoptosis of cervical carcinoma cells, and belongs to the field of medicines. By inhibiting the proliferation of the cervical carcinoma cells and inducing the autophagic apoptosis activity of the cervical carcinoma cells in vitro, an anti-tumor effect of the dendrophenol in resisting the cervical carcinoma cells is detected, and an anti-tumor concentration of the dendrophenol is analyzed, proving that the dendrophenol has an obvious inhibitory effect on the cervical carcinoma cells; therefore, novel medicines for treating human cervical carcinoma can be developed conveniently. The human cervical carcinoma cells are Hela cells. The effective concentration range of the dendrophenol of inhibiting the proliferation of the cervical carcinoma cells and inducing the autophagic apoptosis of the cervical carcinoma cells is 25-200 [mu]mol / L.

This invention generally relates to a design and method for developing novel anti-tumor / cancer drugs, vaccines and therapies, using microRNA (miRNA) and its shRNA homologues / derivatives. More particularly, the present invention relates to the use of a nucleic acid composition capable of expressing mir-302-like gene silencing effectors upon delivery into human cells and then silencing mir-302-targeted cell cycle regulators and oncogenes, resulting in an inhibitory effect on tumor / cancer cell growth and metastasis. Mir-302 is the most predominant miRNA found in human embryonic stem (hES) and induced pluripotent stem (iPS) cells, yet its function is unclear. The present invention establishes that in humans mir-302 concurrently suppressed both cyclin-E-CDK2 and cyclin-D-CDK4 / 6 pathways and eventually blocked over 70% of the G1-S transition. Simultaneously, mir-302 also silences BMI-1, a cancer stem cell marker, and subsequently promotes the tumor suppressor functions of p16Ink4a and p14 / p19Arf in inhibiting CDK4 / 6-mediated cell proliferation. Therefore, the present invention for the first time reveals the tumor suppressor function of mir-302 in humans. This novel finding advances the design and method for developing new cancer drugs, vaccines and therapies directed against multiple kinds of human tumors and cancers, in particular including, but not limited, malignant skin, prostate, breast and liver cancers as well as various tumors.

The present invention addresses the problem of providing a hepatocellular carcinoma marker which can be used for detecting the presence of hepatocellular carcinoma and comprises a glycoprotein that can occur in the liver only when the carcinoma is developed regardless of the change in the condition of the liver. The present invention provides a hepatocellular carcinoma marker which comprises an NPA lectin-binding glycoprotein containing an NPA lectin-binding sugar chain epitope having at least one property selected from the following properties (1) to (5) (1) the sugar chain epitope does not contain core fucose (a fucose alpha 1(arrow) 6 sugar chain); (2) the sugar chain epitope contains a composite sugar chain that contains three (less than four) mannose molecules; (3) the sugar chain epitope does not contain a high-mannose-type sugar chain containing five or more mannose molecules; (4) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to LCA lectin; and (5) the sugar chain epitope comprises a composite sugar chain that does not rely on the bindability to ConA lectin. The presence of the development of hepatocellular carcinoma or the degree of the progression or malignancy of the carcinoma can be determined by detecting the hepatocellular carcinoma marker of the present invention in a sample of interest.

The present invention relates to the novel use of syndecan-2 (SDC2) gene as a CpG methylation biomarker for detecting precancerous lesions, and more particularly, to the use of the SDC2 gene as a biomarker to early diagnose colorectal precancerous lesions by measuring the degree of methylation of the SDC2 gene. The present invention provides a method of providing information for diagnosis of precancerous lesions by detecting methylation of the CpG islands of the SDC2 gene. In addition, the use of the methylation detection and kit according to the present invention makes it possible to diagnose colorectal precancerous lesions at an early transformation stage, thus enabling the early diagnosis of colorectal precancerous lesions. Furthermore, the methylation detection method and kit of the present invention enables colorectal precancerous lesions to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.

The invention relates to microRNA makers for discriminating constitutional lung cancer tissue and paracancerous tissue. More specifically, the invention relates to 38 microRNA markers for discriminating constitutional lung cancer tissue and paracancerous tissue. It has been proved by examination that, these specific microRNA markers can effectively discriminate constitutional lung cancer tissue and paracancerous tissue. The invention also relates to a chip and a test kit for detecting the microRNA markers.

The invention discloses a method for establishing a pancreatic cancer model in a wild-type adult mouse through lentiviruses. The method comprises lentiviral vector construction, virus packaging, titerdetermination and in-vitro verification, virus injection, and pathological identification. The method comprises selecting an oncogene Kras with the highest variation rate of the human pancreatic cancer and cancer suppressor genes of Tp53, Cdkn2a and Cdkn2b, overexpressing the oncogene KrasG12D in the same lentiviral vectors, simultaneously, knocking down Tp53, Cdkn2a and Cdkn2b through shRNA, carrying out virus injection, and after 40 days, detecting significant pancreatic tumors in the adult mouse which is killed by the pancreatic cancer. The method has a short induction period and high andstable incidence, is easy to operate and fast builds the adult mouse pancreatic cancer model. The pancreatic cancer model simulates the genetic mechanism of human pancreatic cancer to the maximum extent, can be used to study the pathogenesis of human pancreatic cancer and the screening of new therapeutic drugs and therapeutic target points and provides a reference for the treatment on human pancreatic cancer.

The invention specifically relates to application of melittin in preparation of a drug used for inhibiting invasion metastasis of breast cancer cells, which belongs to the field of bioengineering technology. CD147 and MMP9 proteins exert significant effects on invasion and metastasis of breast cancer MCF-7 cells. The invention aims to find a CD147 expression inhibitor which is capable of hindering or reducing secretion of MMP9 and inhibiting invasion metastasis of cancer cells to cancerous peripheral tissue. According to the invention, MCF-7 cells are cultured at first, then different doses of melittin is used, and flow cytometry, ELISA and RT-PCR experimental results prove that expression of CD147 and MMP9 is suppressed in the MCF-7 cells treated by melittin; and then Transwell invasion chamber experiments are conducted to detect the migration rate of the MCF-7 cells treated by melittin. Melittin can inhibit invasion metastasis of the MCF-7 cells. Thus, a novel anti-breast cancer drug can be developed from melittin.

Provided are methods of targeting patient-specific oncogenes in extrachromosomal DNA (ecDNA) to treat glioma in a human. The present methods include identifying a drug that targets against an oncogene present in ecDNA of a human suffering from glioma, such as glioblastoma. The identified oncogenes present in ecDNA include MET, MET / CAPZA2, MDM2, CDK4, SOX2, PIK3CA, MECOM, PDGFRA, EGFR, MYCN, MYC, TERT, SMARCA4, RP56, FBXW7, CDK6, CCND2, ERBB2, BRCA1, and BAP1. The present methods include identifying a drug targeted against the ecDNA oncogene, which drug inhibits the function of the identified oncogene, so as to inhibit tumor growth or progression of the glioma in the human. Also provided are PDX mouse models to further identify and / or confirm patient-specific drugs that target the identified oncogene(s) present in ecDNA. Also provided are methods of diagnosing gliomas or recurrent gliomas and methods of screening or monitoring for recurrence of gliomas. Further provided are methods of validating a predicted presence of ecDNA in a brain tumor using fluorescence in situ hybridization (FISH). Also provided are methods of screening drug candidates for a patient by implanting different identified drugs that target an identified oncogene into PDX mouse models.

The invention belongs to the technical field of biology and particularly discloses an oral cancer detection marker and an oral cancer detection kit. The levels of mRNA of CDC6, CDT1, MCM2 and CDC45 in buccal mucosal cells of a normal person, a person with oral inflammation, a person with precancerous lesions, a person with oral cancer and a person at the postoperation period are quantitatively detected, the detection shows that CDC6, CDT1, MCM2 and CDC45 are ideal tumor markers for the screening of the oral cavity in the early stage, and the normal buccal mucosal cells and the canceration exfoliated cells are effectively distinguished. The oral cancer detection marker and the oral cancer detection kit are of great significance for the exploration of the mechanism of the content change of the tumor marker in the buccal mucosal cells and the clinical value of prognosis judgement.

Disclosed herein is a method of treating nuclear protein in testis (NUT) midline carcinoma (NMC) in a subject in need thereof, comprising administering an effective amount of a bromodomain inhibitor, wherein the effective amount can be determined according to the expression levels of CD11b, which monitors responsiveness of the NMC to the bromodomain inhibitor. Also disclosed herein is a method of determining a bromodomain inhibitor treatment regimen in a subject suffering from NMC.